Trial Profile
A Prospective, Multicenter, Two Arms, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 25 mg or 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Mapi Pharma
- 14 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Sep 2026.
- 14 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Aug 2026.
- 14 Nov 2023 Status changed from recruiting to active, no longer recruiting.